KR920002146A - 약학 조성물 - Google Patents

약학 조성물 Download PDF

Info

Publication number
KR920002146A
KR920002146A KR1019910012692A KR910012692A KR920002146A KR 920002146 A KR920002146 A KR 920002146A KR 1019910012692 A KR1019910012692 A KR 1019910012692A KR 910012692 A KR910012692 A KR 910012692A KR 920002146 A KR920002146 A KR 920002146A
Authority
KR
South Korea
Prior art keywords
composition
hydrochloric acid
hydrochloride
pharmaceutical composition
active ingredient
Prior art date
Application number
KR1019910012692A
Other languages
English (en)
Other versions
KR100227156B1 (ko
Inventor
알란 로쓰 브루스
빅터 비빌레치아 리챠드
Original Assignee
쟝 크라머, 한스 루돌프 하우스
산도즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쟝 크라머, 한스 루돌프 하우스, 산도즈 리미티드 filed Critical 쟝 크라머, 한스 루돌프 하우스
Publication of KR920002146A publication Critical patent/KR920002146A/ko
Application granted granted Critical
Publication of KR100227156B1 publication Critical patent/KR100227156B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

약학 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (16)

  1. 분해되기 쉬운 활성 성분과 염산 공여체를 포함하는 약학 조성물.
  2. 제1항에 있어서, 상기 활성 성분이 ACE억제제인 조성물.
  3. 제1항에 있어서, 상기 활성 성분이 스피라프릴인 조성물.
  4. 제1항에 있어서, 상기 활성 성분이 퀴나프릴 또는 에날라프릴인 조성물.
  5. 제1항 내지 제4항중 어느 한 항에 있어서, 상기 활성 성분이 염산 부가염인 조성물.
  6. 제1항 내지 제5항중 어느 한 항에 있어서, 상기 염산 공여체가 아미노산 하이드로클로라이드 또는 루이스산 클로라이드인 조성물.
  7. 제6항에 있어서, 상기 염산 공여체가 글리신 하이드로클로라이드, 글루탐산 하이드로클로라이드, 베타인 하이드로클로라이드, 알라닌, 하이드로클로라이드, 발린 하이드로클로라이드, 라이신 하이드로클로라이드, 아르기닌 하이드로클로라이드, 아스파르트산 하이드로클로라이드, 염화 제2철, 염화 아연 또는 염화 알루미늄인 조성물.
  8. 제6항에 있어서, 상기 염산 공여체가 글리신 하이드로클로라이드인 조성물.
  9. 제1항 내지 제8항중 어느 한 항에 있어서, 상기 염산 공여체가 조성물의 총 중량을 기준으로 1%내지 25%의 양으로 존재하는 조성물.
  10. 제1항 내지 제9항중 어느 한 항에 있어서, 상기 활성 성분 대 염산 공여체의 중량비가 약 2.5:1내지 약 1:7인 조성물.
  11. 제1항 내지 제10항중 어느 한 항에 있어서, 경제 형태인 조성물.
  12. 임의의 한 실시예에 관하여 개시한 바와같이 실질적으로 안정화된 약학 조성물.
  13. 분해되기 쉬운 활성 성분을 염산 공여체로 후처리함을 포함하는, 제1항 내지 제12항중 어느 한 항에 정의된 안정화된 약학 조성물의 제조방법.
  14. 분해되기 쉬운 활성 성분을 함유하는 제1항 내지 제12항중 어느 한 항에 정의된 약학 조성물에 안정화 효과량의 염산 공여체를 혼입시킴을 포함하고, 상기 약학 조성물의 안정화방법.
  15. 제1항 내지 제12항중 어느 한 항에 정의된 약학 조성물에 있어서 분해되기 쉬운 활성 성분을 안정화시키기 위한 염산 공여체의 용도.
  16. 제1항 내지 제12항중 어느 한 항에 정의된, 분해되기 쉬운 활성 성분을 함유하는 약학 조성물의 제조에 있어서 안정제로서의 염산 공여체의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910012692A 1990-07-25 1991-07-24 저장 안정성이 개선된 약학조성물 및 그의 제조방법 KR100227156B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55723490A 1990-07-25 1990-07-25
US557,234 1990-07-25

Publications (2)

Publication Number Publication Date
KR920002146A true KR920002146A (ko) 1992-02-28
KR100227156B1 KR100227156B1 (ko) 1999-10-15

Family

ID=24224569

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910012692A KR100227156B1 (ko) 1990-07-25 1991-07-24 저장 안정성이 개선된 약학조성물 및 그의 제조방법

Country Status (30)

Country Link
EP (1) EP0468929B1 (ko)
JP (1) JP2502849B2 (ko)
KR (1) KR100227156B1 (ko)
AT (1) AT400519B (ko)
AU (1) AU639354B2 (ko)
CA (1) CA2047802C (ko)
CH (1) CH683150A5 (ko)
CZ (1) CZ280184B6 (ko)
DE (1) DE4124409B4 (ko)
DK (1) DK0468929T3 (ko)
ES (1) ES2061218T3 (ko)
FI (1) FI98127C (ko)
GB (1) GB2246296B (ko)
HU (1) HU222489B1 (ko)
IE (1) IE66184B1 (ko)
IL (1) IL98934A (ko)
IT (1) IT1290797B1 (ko)
LU (1) LU87980A1 (ko)
MX (1) MX9100357A (ko)
MY (1) MY107183A (ko)
NO (1) NO912872D0 (ko)
NZ (1) NZ239078A (ko)
PL (1) PL167712B1 (ko)
PT (1) PT98417B (ko)
RU (1) RU2075310C1 (ko)
SA (1) SA92130106B1 (ko)
SK (1) SK278563B6 (ko)
TW (1) TW212757B (ko)
UA (1) UA26064A1 (ko)
ZA (1) ZA915861B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100483080B1 (ko) * 2001-09-21 2005-04-14 한인규 염산·베타인(betaine·HCl), 판크레아틴, 제2인산 칼슘, 크롬 피콜리네이트, 락토바실러스속·비피도박테리아속·스트렙토코커스속·프럭토 올리고당, 비타민, 미네랄을 유효성분으로 구성된 것을 특징으로 하는 증체개선용 영양강화 사료첨가제

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789597A (en) * 1994-07-13 1998-08-04 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Process for the preparation of compounds having ACE inhibitory action and intermediates in said process
DE4444051A1 (de) * 1994-12-10 1996-06-13 Rhone Poulenc Rorer Gmbh Pharmazeutische, oral anwendbare Zubereitung
HU222497B1 (hu) * 1996-12-18 2003-07-28 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Enalapril-maleátot tartalmazó stabilizált gyógyszerkészítmény és eljárás előállítására
BR9910947A (pt) * 1998-06-05 2001-03-06 Warner Lambert Co Estabilização de composições que contêm inibidores de ace utilizando óxido de magnésio
US6462022B1 (en) † 2001-09-24 2002-10-08 Astrazeneca Ab Lisinopril compositions having large-particle DCPD
ATE357933T1 (de) * 2002-01-15 2007-04-15 Actavis Group Hf Formulierungen von quinapril und verwandte ace- hemmer
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
EP3630084A1 (en) 2017-05-31 2020-04-08 Boehringer Ingelheim International GmbH Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB895027A (en) * 1959-08-03 1962-04-26 Bristol Myers Co Therapeutic tetracycline compositions
GB1437788A (en) * 1973-01-31 1976-06-03 Gist Brocades Nv Therapeutic compositions
HU173823B (hu) * 1975-07-25 1979-08-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija stabil'nogo lechebnogo preparata dlja oral'noj dozirovki, kotoryj soderzhit proizvodnyj gomopirimidazola
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
US4442089A (en) * 1982-07-06 1984-04-10 E. R. Squibb & Sons, Inc. Method for treating glaucoma with topical or systemic ACE inhibitor compositions
US4575539A (en) * 1985-06-03 1986-03-11 E. R. Squibb & Sons, Inc. Drug delivery systems including novel interpenetrating polymer networks and method
US4900559A (en) * 1985-12-12 1990-02-13 Briston-Myers Company Stabilized enteric coated aspirin granules and process of preparation
DE3627613A1 (de) * 1986-08-14 1988-02-18 Merck Patent Gmbh Pharmazeutische zubereitung
US4793998A (en) * 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
US4830853A (en) * 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
JP2603480B2 (ja) * 1987-08-05 1997-04-23 住友製薬株式会社 安定化されたアンスラサイクリン系製剤
AU608891B2 (en) * 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
US4912096A (en) * 1989-06-26 1990-03-27 E. R. Squibb & Sons, Inc. Method for preventing or treating depression employing an ace inhibitor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100483080B1 (ko) * 2001-09-21 2005-04-14 한인규 염산·베타인(betaine·HCl), 판크레아틴, 제2인산 칼슘, 크롬 피콜리네이트, 락토바실러스속·비피도박테리아속·스트렙토코커스속·프럭토 올리고당, 비타민, 미네랄을 유효성분으로 구성된 것을 특징으로 하는 증체개선용 영양강화 사료첨가제

Also Published As

Publication number Publication date
ZA915861B (en) 1993-03-31
PL167712B1 (en) 1995-10-31
TW212757B (ko) 1993-09-11
ITRM910554A0 (it) 1991-07-23
CS230991A3 (en) 1992-04-15
DE4124409A1 (de) 1992-01-30
IT1290797B1 (it) 1998-12-11
NO912872D0 (no) 1991-07-23
FI913554A (fi) 1992-01-26
ES2061218T3 (es) 1994-12-01
PT98417B (pt) 1999-01-29
HU9102385D0 (en) 1991-12-30
IE66184B1 (en) 1995-12-13
DE4124409B4 (de) 2004-11-18
JPH04253923A (ja) 1992-09-09
CZ280184B6 (cs) 1995-11-15
AT400519B (de) 1996-01-25
DK0468929T3 (da) 1994-12-27
MX9100357A (es) 1992-02-28
MY107183A (en) 1995-09-30
PT98417A (pt) 1992-06-30
EP0468929A2 (en) 1992-01-29
NZ239078A (en) 1993-10-26
GB2246296A (en) 1992-01-29
GB2246296B (en) 1994-04-06
CA2047802A1 (en) 1992-01-26
AU8128691A (en) 1992-01-30
IL98934A0 (en) 1992-07-15
SK278563B6 (en) 1997-10-08
AU639354B2 (en) 1993-07-22
CA2047802C (en) 2003-05-06
KR100227156B1 (ko) 1999-10-15
EP0468929A3 (en) 1992-02-19
LU87980A1 (fr) 1993-02-15
EP0468929B1 (en) 1994-09-28
FI98127C (fi) 1997-04-25
SA92130106B1 (ar) 2005-10-16
HU222489B1 (hu) 2003-07-28
ITRM910554A1 (it) 1993-01-23
ATA147691A (de) 1995-06-15
FI913554A0 (fi) 1991-07-24
CH683150A5 (de) 1994-01-31
GB9115893D0 (en) 1991-09-04
FI98127B (fi) 1997-01-15
UA26064A1 (uk) 1999-04-30
PL291219A1 (en) 1992-08-24
IL98934A (en) 1996-07-23
RU2075310C1 (ru) 1997-03-20
IE912608A1 (en) 1992-01-29
HUT59819A (en) 1992-07-28
JP2502849B2 (ja) 1996-05-29

Similar Documents

Publication Publication Date Title
KR920002146A (ko) 약학 조성물
EE04223B1 (et) Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid
ATE149349T1 (de) Einarbeitung eines poly-n-vinylamids in ein transdermales system
WO1998052614A3 (en) Composition and method for enhancing transport across biological membranes
EA199700277A1 (ru) Соединения, ингибирующие фарнезил-протеинтрансферазу, и фармацевтическая композиция на их основе
ID21956A (id) Asam n-(aril dan atau heteroarilasetil) amino ester, komposisi farmasi yang mengandungnya, dan metoda untuk menghambat pelepasan betha-amiloid peptida dan atau sintesanya dengan menggunakan senyawa tersebut
KR970005043B1 (en) Tumor necrosis factor alpha muteins
KR950024769A (ko) 고농도 tcf 제제
DE69500490D1 (de) Glattmuskelrelaxierende Arzneizubereitungen
AU784885B2 (en) Dry compositions containing hydrophobic amino acid
KR970073601A (ko) 생리 활성 펩티드 함유 경비 투여용 조성물
NO179126B (no) Farmasöytisk preparat omfattende en ACE-inhibitor og en saltsyredonor, samt fremgangsmåte for fremstilling av slike stabiliserte preparater
KR950010909A (ko) 면역글로불린 e 생성 억제용 조성물
EP0740935A4 (en) STIMULATOR OF ANALGESIC ACTIVITY
EA199900551A1 (ru) Фармацевтическая композиция, содержащая ингибитор иммуноглобулин-рецепторного взаимодействия
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
US3639383A (en) Complexes of a.c.t.h. peptides and polyphosphoric acids
KR900014429A (ko) 폴리펩티드 유도체 및 칼슘 대사 향진제
EA200500187A1 (ru) Фармацевтическая композиция для лечения токсической невропатии
KR970058720A (ko) 향균 및 항진균 활성을 갖는 펩타이드
KR970073571A (ko) 키토산 올리고당과 아미노산과의 복합체를 함유하는 화장료 조성물
GB1479017A (en) Polyptides process for their manufacture and their use as polyvalten inhibitors
LaCross The kinetics of amino acid uptake and protein synthesis in isolated mitochondria of Tetrahymena pyriformis GL.
KR960030911A (ko) 아미노프로판 인산 또는 그 염을 함유하는 화장료 조성물
Yeung-Joon et al. Changes Occurred in Protein and Amino Acid Compositions during Postmortem Aging of White and Dark Muscle of Yellowtail at $2^{\circ} C$

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100729

Year of fee payment: 12

EXPY Expiration of term